{
  "abstract": "Background and Importance Haemophilia is a chronic bleeding disorder that profoundly impacts patients‘ physical health and overall quality of life. Managing this condition not only addresses treatment bleeding episodes but also supports long-term health and functioning.Aim and Objectives To evaluate treatment adherence and quality of life in patients receiving clotting factors. The study aims to describe patient characteristics, assess treatment effectiveness, adverse effects and determine adherence levels and satisfaction.Material and Methods Multicentre cross-sectional study that included all patients treated with clotting factors since their introduction in hospital guidelines. Data collected: sex, age, comorbidities, bleeding episodes, adherence (non-adherence: <80% adherence rate)and adverse effects. Quality of life was evaluated using the WHOQOL-BREF questionnaire (26 items) and the Haem-A-Qol(46 items divided into 10 domains).Statistical analysis was performed using R software. Exclusion criteria were psychiatric disorders, psychiatric medication use or unwillingness to participate.Results Forty-one male patients were analysed. Median age 35 years. Thirty-five had haemophilia A and 6 haemophilia B.Twenty-seven patients were on prophylactic treatment, while 14 received on-demand. Twelve patients were treated with emicizumab, six efmoroctocog alfa, six lonoctocog alfa, five turoctocog alfa, four albutrepenonacog alfa, three simoctocog alfa, two efanesoctocog, three nonacog and one heptacog. Comorbidities were diabetes mellitus (17.5%), hypertension (16.3%), hepatitis C (9.3%) and HIV (2.3%). Of the patients on prophylactic treatment, 98.7% were adherent. Median overall score of the WHOQOL-BREF questionnaire was 69, with the highest score in social relationships (65) and the lowest in psychological health (52). Haem-A-QoL assessment yielded an average score of 47.5 indicating a moderate impact of haemophilia on daily life. The best-rated domains were family interaction (12.0) and coping (14.2), suggesting strong social support and effective disease management. Cronbach’s alpha was 0.75, indicating good internal consistency. Patients treated with emicizumab showed higher scores compared to the rest. In the WHOQOL-BREF, they achieved a median score of 75, with the highest in physical health (71). Similarly, in the Haem-A-QoL questionnaire, they obtained an average score of 42.3, indicating a lower impact of haemophilia on daily life.Conclusion and Relevance Subcutaneous coagulation factor treatment, including emicizumab, improved adherence and quality of life in haemophilia patients, particularly in social and coping domains. Strong family support and effective coping strategies contributed to better well-being. The study supports the continued use of subcutaneous therapies for optimised patient care.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Clínico Universitario De Valladolid, Servicio De Farmacia, Valladolid, Spain"
      ],
      "name": "A Martín Roldán"
    },
    {
      "affiliations": [
        "Hospital Comarcal De Baza, Pharmacy, Granada, Spain"
      ],
      "name": "MDM Sánchez Suárez"
    },
    {
      "affiliations": [
        "Hospital Universitario Virgen De Las Nieves, Pharmacy, Granada, Spain"
      ],
      "name": "C Alarcón Payer"
    },
    {
      "affiliations": [
        "Hospital Clínico Universitario De Valladolid, Pharmacy, Valladolid, Spain"
      ],
      "name": "S Maganto Garrido"
    },
    {
      "affiliations": [
        "Hospital Universitario Virgen De Las Nieves, Pharmacy, Granada, Spain"
      ],
      "name": "A Jiménez Morales"
    }
  ],
  "title": "4CPS-087 Optimising haemophilia management: enhancing treatment adherence and quality of life with innovative therapies",
  "uid": "186b16c3-b1eb-594e-a1ca-0ef9d10d2d23"
}